article thumbnail

Alnylam Promotes Pushkal Garg to Chief R&D Officer

The Pharma Data

Alnylam Elevates Dr. Pushkal Garg to Lead Unified Research and Development Organization, Signaling Strategic Expansion into Next Phase of RNAi Therapeutics Innovation Alnylam Pharmaceuticals , a global leader in RNA interference (RNAi) therapeutics, has announced the promotion of Pushkal Garg, M.D.,

RNA 40
article thumbnail

EAACI: Dupixent Supersedes Xolair in CRS w/ Nasal Polyps and Asthma Phase 4 Head-to-Head Study

The Pharma Data

Sanofi and Regeneron’s Dupixent Shows Superiority over Xolair in First-Ever Head-to-Head Phase 4 Study in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Co-existing Asthma Sanofi and Regeneron Pharmaceuticals, Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Oncology advances through the lens of women in STEM

Drug Target Review

This field allowed me the privilege of tending to children in the hospital and building long-term relationships with them and their families. Pooja transitioned to the pharmaceutical industry to broaden her impact on patient care, leveraging her expertise to help develop innovative cancer treatments.

article thumbnail

Fixing drug discovery’s most persistent problem with AI

Drug Target Review

The pharmaceutical industry is facing pressure on multiple fronts: increasingly scarce early-stage funding, growing competition from Chinese biotech companies, and a traditional drug discovery process that remains inefficient and expensive.”

article thumbnail

FDA Grants Accelerated Approval to Lynozyfic™ for Relapsed or Refractory Multiple Myeloma

The Pharma Data

FDA Grants Accelerated Approval to Regeneron’s Lynozyfic™ (linvoseltamab-gcpt) for Relapsed or Refractory Multiple Myeloma Regeneron Pharmaceuticals has secured a critical milestone in oncology drug development with the U.S. This connection triggers targeted T-cell activation and destruction of cancerous plasma cells.

FDA 40
article thumbnail

Ladders to Cures (L2C) Accelerator

Broad Institute

As a proof of concept, a drug designed to target a newly discovered biological node is showing efficacy in treating rare genetic diseases in the kidney, the eye, and the brain and is now making its way to clinical trials in collaboration with a pharmaceutical partner.

article thumbnail

2025: Perspectives and Predictions From Advarra Thought Leaders

Advarra

There are varied opinions about site consolidation, but I would like to add some perspective: Pharmaceutical companies routinely buy up small pharmaceutical and biotech companies and add them to their portfolio. Site consolidation is much the same. It has its pros and cons, but I will speak to the positives of such consolidation.